Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
JJ Miller, LN Gonzalez Castro, S McBrayer… - Neuro …, 2023 - academic.oup.com
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of …
Abstract The 2016 and 2021 World Health Organization 2021 Classification of central
nervous system tumors have resulted in a major improvement in the classification of …
nervous system tumors have resulted in a major improvement in the classification of …
Tumor volume growth rates and doubling times during active surveillance of IDH-mutant low-grade glioma
Purpose: Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain
tumors characterized by a slow-growing phase over several years followed by a rapid …
tumors characterized by a slow-growing phase over several years followed by a rapid …
Impact of frontline ivosidenib on volumetric growth patterns in isocitrate dehydrogenase–mutant astrocytic and oligodendroglial tumors
Abstract Purpose: Isocitrate dehydrogenase (IDH)-mutant gliomas are usually treated with
radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae …
radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae …
IDH-mutant low-grade glioma: advances in molecular diagnosis, management, and future directions
A Dono, LY Ballester, D Primdahl, Y Esquenazi… - Current oncology …, 2021 - Springer
Purpose of Review IDH-mutant low-grade gliomas (LGG) have emerged as a distinct clinical
and molecular entity with unique treatment considerations. Here, we review updates in IDH …
and molecular entity with unique treatment considerations. Here, we review updates in IDH …
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors
BM Ellingson, ER Gerstner, AB Lassman… - Neuro …, 2022 - academic.oup.com
Imaging response assessment is a cornerstone of patient care and drug development in
oncology. Clinicians/clinical researchers rely on tumor imaging to estimate the impact of new …
oncology. Clinicians/clinical researchers rely on tumor imaging to estimate the impact of new …
Balancing risk and efficiency in drug development for rare and challenging tumors: a new paradigm for glioma
IK Mellinghoff, TF Cloughesy - Journal of Clinical Oncology, 2022 - ascopubs.org
The process of developing cancer therapies is well established and has enabled the
incorporation of many new drugs and classes of agents into the standard of care for common …
incorporation of many new drugs and classes of agents into the standard of care for common …
NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials …
AH Abayazeed, A Abbassy, M Müeller… - Neuro-oncology …, 2023 - academic.oup.com
Background Accurate and repeatable measurement of high-grade glioma (HGG) enhancing
(Enh.) and T2/FLAIR hyperintensity/edema (Ed.) is required for monitoring treatment …
(Enh.) and T2/FLAIR hyperintensity/edema (Ed.) is required for monitoring treatment …
Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery
G Cassinelli Petersen, K Bousabarah… - Neuro-Oncology …, 2022 - academic.oup.com
Background Treatment of brain metastases can be tailored to individual lesions with
treatments such as stereotactic radiosurgery. Accurate surveillance of lesions is a …
treatments such as stereotactic radiosurgery. Accurate surveillance of lesions is a …
[HTML][HTML] AI-Driven image analysis in central nervous system tumors-traditional machine learning, deep learning and hybrid models
The interpretation of imaging in medicine in general and in oncology specifically remains
problematic due to several limitations which include the need to incorporate detailed clinical …
problematic due to several limitations which include the need to incorporate detailed clinical …